http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Avalon GloboCare (AVCO) Receives Allowance for Joint U.S. Patent
-
Avalon GloboCare Receives Allowance for Joint U.S. Patent
-
Avalon GloboCare (AVCO) Reports Publication Featuring QTY Code Technology
-
Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society
-
Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society
-
Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
-
Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
-
Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference
-
Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference
-
Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy
-
Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy
-
Avalon GloboCare (AVCO) Files 16 New Patent Applications
-
Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications
-
Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications
-
Avalon GloboCare (AVCO) Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer Cell Therapies
-
Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies
-
Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies
-
Avalon GloboCare (AVCO) Provides Year-End Business Update of Selective Scientific and Clinical Programs
-
Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
-
Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
-
Avalon GloboCare's (AVCO) Chairman Converts $3M of Debt into Common Stock $1.25/sh
-
Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to Market
-
Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to Market
-
Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development
-
Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development
-
Avalon GloboCare (AVCO) Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
-
Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
-
Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
-
Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for
-
Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for
-
Avalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30th
-
Avalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30th
-
UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare
-
UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare
-
Avalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in Recurrent Brain Cancer
-
Avalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in Recurrent Brain Cancer
-
Avalon GloboCare (AVCO) CEO Provides Letter to Update Shareholders About Acquisition of SenlangBio
-
Avalon GloboCare CEO Provides Letter to Update Shareholders About Acquisition of SenlangBio
-
Avalon GloboCare CEO Provides Letter to Update Shareholders About Acquisition of SenlangBio
-
Avalon GloboCare (AVCO) Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction
-
Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction
-
Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction
-
Avalon GloboCare to Present at the Noble Capital Markets Investor Forum During the 16th Annual World Stem Cell Summit on June 17, 2021
-
Avalon GloboCare to Present at the Noble Capital Markets Investor Forum During the 16th Annual World Stem Cell Summit on June 17, 2021
-
Avalon GloboCare To Present Its S-Layer and QTY Code Breakthrough Technology Platforms at The Prestigious Annual World Stem Cell Summit
-
Avalon GloboCare To Present Its S-Layer and QTY Code Breakthrough Technology Platforms at The Prestigious Annual World Stem Cell Summit
-
Avalon GloboCare (AVCO) Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Advance Clinical Development of Cellular Immunotherapies Using the FLASH-CAR P
-
Avalon GloboCare Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Advance Clinical Development of Cellular Immunotherapies Using the FLASH-CAR™ Plat
-
Avalon GloboCare Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Advance Clinical Development of Cellular Immunotherapies Using the FLASH-CAR™ Plat
-
Avalon GloboCare Expands Co-Development Program with MIT to Combat Cancer Metastasis

